10-Q: Barinthus Bio Reports Q3 Loss, Advances Celiac Trial, Eyes Clywedog Merger

Barinthus Biotherapeutics reported a net loss of $14.6 million for Q3 2025, continued progress in its VTP-1000 celiac disease trial, and detailed its pending all-stock merger with Clywedog Therapeutics.

Summary

• Net loss for the three months ended September 30, 2025, was $14.6 million, compared to $8.1 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $55.4 million, compared to $40.6 million for the same period in 2024.
• Total revenue for both the three and nine months ended September 30, 2025, was nil, a significant decrease from $15.0 million in the corresponding periods of 2024, primarily due to the withdrawal of marketing authorization for Vaxzevria.
• Cash, cash equivalents, and restricted cash totaled $75.7 million as of September 30, 2025, down from $112.4 million at the beginning of the year.
• An impairment charge of $4.7 million was recorded for acquired development technology intangible assets during Q3 2025, triggered by the indicative offer price of the merger being below prior valuations.
• The company entered into a definitive all-stock merger agreement with Clywedog Therapeutics, Inc. on September 29, 2025, with the combined entity to be renamed Clywedog Therapeutics Holdings, Inc. and trade under the ticker symbol CLYD on Nasdaq.
• Strategic focus has shifted to autoimmune and inflammatory diseases (I&I), with the lead candidate VTP-1000 for celiac disease currently in a Phase 1 clinical trial.
• Infectious disease and oncology programs, including VTP-300 (HBV) and VTP-850 (Prostate cancer), have been deprioritized, with the company seeking partners for their continued development.
• The UK laboratory operations in Harwell, Oxfordshire, ceased in August 2025, and the remaining clinical and operational workforce is transitioning to remote roles.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to increased losses, zero revenue, and a significant impairment charge. However, the announced merger with Clywedog and the strategic focus on I&I, coupled with ongoing clinical trial progress for VTP-1000 and a cash runway into early 2027 (standalone), provide a structured path forward and mitigate a more severe negative rating.

Positives

• The VTP-1000 celiac disease Phase 1 single ascending dose (SAD) trial is ongoing with no treatment-related serious adverse events reported to date.
• The multiple ascending dose part of the VTP-1000 Phase 1 trial has commenced enrolling patients, indicating progress in clinical development.
• The strategic combination with Clywedog Therapeutics aims to create a company with a novel portfolio targeting metabolic and autoimmune diseases, with four clinical data milestones expected within 18 months of the closing.
• The combined company will be supported by existing cash and additional investments from existing Clywedog shareholders (OrbiMed and TPAV, LLC) and new investors.
• Received $3.6 million in cash related to the 2024 research and development (R&D) tax credit in October 2025, improving liquidity post-period end.

Negatives

• Net loss increased significantly to $14.6 million for Q3 2025 and $55.4 million for the nine months ended September 30, 2025, compared to prior periods.
• Revenue declined to nil for Q3 and YTD 2025, from $15.0 million in 2024, due to the withdrawal of Vaxzevria marketing authorization by AstraZeneca.
• Cash, cash equivalents, and restricted cash decreased by $36.7 million during the nine months ended September 30, 2025.
• A $4.7 million impairment charge was recorded on acquired development technology intangible assets due to the merger agreement's indicative offer price being below prior valuations.
• General and administrative expenses increased by $6.6 million for the nine months ended September 30, 2025, primarily due to increased professional fees for strategic activity and foreign exchange losses.
• The company's at-the-market (ATM) facility for raising capital expired on August 17, 2025, and is no longer available as a source of liquidity.
• Deprioritization of infectious disease and oncology programs indicates a narrowing of the pipeline and potential loss of value from those assets.

Risks

• Failure to complete the Contemplated Transactions with Clywedog would have a material adverse effect on the business, results of operations, financial condition, and stock price.
• The inability to obtain necessary approvals (shareholder, regulatory, Court sanction) for the merger could prevent its consummation.
• Potential shareholder litigation and other legal and regulatory proceedings related to the merger could cause delays or prevent its completion.
• Difficulties in successfully integrating the businesses of Barinthus Bio and Clywedog could adversely affect future business and financial performance, including managing a larger company, coordinating operations, retaining key personnel, and integrating systems.
• Existing shareholders may experience substantial dilution of their ownership interests in the combined company (expected to own approximately 34% of Topco) without receiving commensurate benefits.
• The business is exposed to inherent risks during the period prior to closing the merger, such as disruption to operations, inability to attract and retain key personnel, and restrictions on business activities under the Merger Agreement.
• Inadequate funding for U.S. government agencies (FDA, SEC) due to government shutdowns or other disruptions could hinder product development, regulatory reviews, and business operations.
• Changes in U.S. tax law, such as the One Big Beautiful Bill Act (OBBBA) and Section 174 capitalization of R&D expenses, could adversely affect financial condition and results of operations.
• Healthcare legislative or regulatory reform measures (e.g., Executive Order 14273, 14297, state-level pricing controls) may prevent or delay marketing approval, restrict post-approval activities, and affect profitability.
• Shareholder protections under the U.K. City Code on Takeovers and Mergers may not apply if the company's central management and control is considered outside the U.K. (though this will change from February 3, 2027).

Future Outlook

The company expects to incur losses and negative cash flows from operations for the foreseeable future as it advances product candidates through clinical development and seeks regulatory approval. Existing cash, cash equivalents, and restricted cash are projected to fund standalone operations into early 2027. The pending merger with Clywedog Therapeutics, expected to close in the first half of 2026, aims to create a combined entity focused on metabolic and autoimmune diseases, with four clinical data milestones anticipated within 18 months of closing. The combined company will be renamed Clywedog Therapeutics Holdings, Inc. and trade under CLYD. Data from the VTP-1000 SAD phase is expected before the end of 2025, and from the multiple ascending dose part in the second half of 2026. The company intends to exit the CEPI Funding Agreement for the VTP-500 MERS program and is seeking partners for VTP-300 (HBV) and VTP-850 (Prostate cancer) programs.

Management Comments

• "Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We aim to achieve this by developing truly transformational and highly disease-specific immunotherapies."
• "We believe our core capabilities at the intersection of T cell immunology and immunotherapeutic technology platforms combined with our track record of successfully executing development path activities uniquely position us to navigate towards delivering promising new treatments for patients with autoimmune and inflammatory diseases and building value for shareholders."
• "Based on our current standalone research and development plans, we expect that our existing cash, cash equivalents, restricted cash and other financial resources will enable us to fund our operating expenses and capital expenditure requirements into the start of 2027."
• "We anticipate announcing data from the SAD phase of the trial [VTP-1000] before the end of 2025."
• "The multiple ascending dose part of the Phase I Avalon clinical trial has commenced enrolling patients, and data are expected in the second half of 2026."
• "We intend to exit the Funding Agreement [CEPI] as part of aligning resources in accordance with the Company's strategy."
• "We are currently seeking partners to fund or collaborate on certain of our programs, including VTP-300 and VTP-850, which we do not intend to develop beyond the completion of the ongoing trials, as applicable."

Industry Context

The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements. Barinthus Bio's strategic shift to focus solely on autoimmune and inflammatory diseases (I&I) with its SNAP-TI platform aligns with a growing industry trend towards specialized therapeutic areas with significant unmet medical needs. The all-stock merger with Clywedog Therapeutics, also focused on metabolic and autoimmune diseases, reflects a broader industry movement towards consolidation to create more robust pipelines and leverage combined resources, particularly in capital-intensive drug development. The deprioritization of infectious disease and oncology programs suggests a strategic decision to concentrate resources where the company believes it has the strongest competitive advantage or market opportunity.

Legal Proceedings

• The company does not believe it is party to any claim or litigation that would individually or in the aggregate be reasonably expected to have a material adverse effect on its business as of September 30, 2025.
• From time to time, the company could be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.
• Litigation may arise in connection with the Contemplated Transactions, which could be costly, prevent consummation of the merger, divert management's attention, and otherwise materially harm the business.

Related Party Transactions

• Recognized nil license revenue from Oxford University Innovation Limited (OUI) for the three and nine months ended September 30, 2025 (compared to $15.0 million in the corresponding 2024 periods).
• Incurred expenses related to clinical study costs of $0.1 million and $0.4 million for the three and nine months ended September 30, 2025, respectively, from Oxford University Innovation Limited (compared to $0.2 million and $0.7 million in the corresponding 2024 periods).

Stakeholder Impact

• Shareholders: Expected to experience substantial dilution, owning approximately 34% of the combined company (Topco). The value of their investment will depend on the successful completion and integration of the merger and the performance of the combined entity's pipeline. Barinthus's ordinary shares will be delisted from Nasdaq.
• Employees: A reduction in headcount has occurred, contributing to decreased personnel-related expenses. The UK workforce is transitioning to remote roles. Restricted stock units (RSUs) were granted to support employee retention and alignment with shareholder interests.
• Customers/Patients: The strategic focus on autoimmune and inflammatory diseases through the combined company's pipeline offers potential new treatments. However, the deprioritization of infectious disease and oncology programs means less focus on those areas.
• Creditors: The overall financial health and successful execution of the merger will influence the company's ability to meet its obligations.

Next Steps

• Announce data from the VTP-1000 single ascending dose (SAD) phase before the end of 2025.
• Continue enrolling patients for the VTP-1000 multiple ascending dose part of the Phase 1 trial, with data expected in the second half of 2026.
• Complete the all-stock merger with Clywedog Therapeutics, Inc., expected in the first half of 2026.
• Topco (the combined company) will apply to list its common stock on Nasdaq.
• The combined company expects to achieve four clinical data milestones within 18 months of the merger closing.
• Seek a partner or collaborator for the VTP-300 (HBV) and VTP-850 (Prostate cancer) programs.
• Intend to exit the CEPI Funding Agreement for the VTP-500 MERS program as part of strategic realignment.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation via an all-stock merger with Clywedog Therapeutics, shifting its focus entirely to autoimmune and inflammatory diseases. While current financial results show increased losses and a complete loss of prior license revenue, the merger aims to create a more focused entity with a broader pipeline and additional funding. The immediate future is dominated by merger execution and clinical trial milestones. Investors should hold to observe the successful completion of the merger, the integration process, and the initial clinical data readouts from the combined entity's pipeline, particularly VTP-1000, before making further investment decisions. The dilution for existing shareholders and the risks associated with integrating two companies warrant caution, but the potential for a stronger, more focused combined entity prevents a 'sell' recommendation at this stage.

Keywords

Biotherapeutics, Immunotherapy, Celiac Disease, Autoimmune, Inflammation, SNAP-TI, VTP-1000, Clywedog Therapeutics, Merger, SEC Filing, 10-Q, Clinical-stage, Pharmaceutical, Biotechnology, R&D, Financial Results, Nasdaq